Startups
ResoTher Pharma
Holte, Denmark
ResoTher Pharma is a Danish clinical-stage biotechnology company developing peptide-based resolution therapies to modulate inflammatory responses in acute cardiovascular disease. Its exact legal entity is ResoTher Pharma A/S, CVR37852406, formerly styled ApS in historical financing announcements, based in Holte nearCopenhagen. Its lead investigational compound RTP-026 is an AnnexinA1-derived FPR2 agonist being studied as a potential cardioprotective treatment in patients with acute myocardial infarction; issuer-reported2026Phase2a findings are research results, not regulatory approval or established clinical effectiveness. The scientific programme originates in research at the WilliamHarveyResearchInstitute and QueenMaryUniversityofLondon. This is deep biotechnology/drug-development coverage; direct AIsoftware or neuroscience product claims are not established. Current own public management names CEOAndersKronborg, CFOHanneVissingLeth and CMOMortenLindJensen. The published board includes chairBeckiMorison, ThomasJonassen, JeppeØvliØvlesen, HenrikStage, MichaelØsterlundMadsen, SvenJacobson and RoderickFlower. External scientific advisers are distinguished from employees; ThomasJonassen is also explicitly listed asChiefScienceOfficer. Co-foundersThomasJonassen andJeppeØvlesen’s2017CSO/CFO roles and formerCEOLoneVeng are historical; old leadership posts are not used to overwrite current2026 management. A2017seed financing signed withCAPNOVA aslead has undisclosed cash amount; the November2019DKK16.5M combined financing comprises equity and three grants, so it is not entered as pure equity or additional cash on topof its grant components. A completedMay2021share issue raisedDKK38.8M. ExactEUproject grants and received advances are distinguished from roundedawardannouncements and are not duplicated. The2024signedannualreport provides legalidentity and historicalfunding evidence, while2025plannedshareissuance commitments are not assumed cashcloses. HunterCapitalRTO1’s March2026 reverse-takeover LetterofIntent remained an intended all-share transaction: itsSeptember30,2026 announcement extends theLOI throughDecember31,2026. ResoTher separately completedapproximatelySEK14.8M bridgefinancing announcedJuly6,2026; no investor allocation or plannedlargerRTO financing/valuation is inferred as paid issuer cash. No completed public listing or merger withHunter is asserted.
Team
 Anders KronborgChief Executive Officer |
Anthony MathurScientific Advisory Board Member (external) |
 Becki MorisonBoard Chair |
 Hanne Vissing LethChief Financial Officer |
 Henrik StageBoard Member |
 Jeppe Øvli ØvlesenBoard Member · Co-Founder; former Chief Financial Officer (historical, 2017) |
 Lone VengFormer Chief Executive Officer (historical, 2017–early2023) |
 Mauro PerrettiScientific Advisory Board Member (external) |
 Michael Østerlund MadsenBoard Member |
 Morten Lind JensenChief Medical Officer |
 Oliver SoehnleinScientific Advisory Board Member (external) |
 Roderick FlowerBoard Member |
 Sven JacobsonBoard Member |
 Thomas JonassenBoard Member · Chief Science Officer · Co-Founder (historical founding role) |